Philip Beachy - Stanford CA, US David Berman - Baltimore MD, US Sunil Karhadkar - Towson MD, US Edward Schaeffer - Baltimore MD, US Angelo DeMarzo - Baltimore MD, US
Assignee:
Johns Hopkins University - Baltimore MD
International Classification:
C12Q 1/02 G01N 33/53
US Classification:
435007100, 435029000
Abstract:
Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in prostate tumors, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a prostate cancer associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of identifying a prostate tumor of a subject as, or as capable of becoming lethal and/or metastatic.
Compare-Ms: Method Rapid, Sensitive And Accurate Detection Of Dna Methylation
William G. Nelson - Towson MD, US Xiaohui S. Lin - Redland CA, US Angelo M. Demarzo - Baltimore MD, US
International Classification:
C12Q 1/68 C12P 19/34
US Classification:
435 6, 435 915
Abstract:
The present invention provides methods and kits useful for enriching, identifying and quantifying methylated DNA3 particularly hypermethylated CpG islands by digesting a sample with a methylation-sensitive restriction endonuclease and capturing methylated restriction fragments with a methyl-binding capture reagent. The methods of the invention may be used in the detection of cancer, particularly detection of prostate cancer.
Michael Christoph Haffner - Baltimore MD, US Alcides Chaux - Baltimore MD, US William G. Nelson - Towson MD, US Angelo M. DeMarzo - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
G01N 33/574
US Classification:
435 611
Abstract:
The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for diagnosing or predicting cancer in a patient. In one embodiment, a method for identifying a patient as having cancer comprises the steps of (a) providing a formalin-fixed, paraffin-embedded or fresh frozen sample of patient tissue; (b) steaming the sample in antigen retrieval buffer; (c) incubating the sample in hydrochloric acid (HCl); (d) incubating the sample with an affinity reagent specific for 5hmC under conditions to form a complex between the affinity reagent and 5-hydroxymethylcytosine (5hmC) present in the sample; (e) detecting the complexes formed between 5hmC and the affinity reagent with secondary detection reagents; (f) quantifying 5hmC levels; and (g) identifying the patient as having cancer if the 5hmC levels in the sample are reduced as compared to a control.